Cardiovascular Effectiveness of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Routine Care of Frail People with Type 2 Diabetes

被引：0
|
作者：
Kutz, Alexander
Gopalakrishnan, Chandrasekar
Kim, Dae H.
Patorno, Elisabetta
机构：
来源：
DIABETES | 2022年 / 71卷
关键词：
D O I：
10.2337/db22-1082-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1082-P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes
    Kuang, Zengguang
    Hou, Ningning
    Kan, Chengxia
    Han, Fang
    Qiu, Hongyan
    Sun, Xiaodong
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2023, 55 (03) : 617 - 629
  • [42] Comparative effectiveness of GLP-1 Receptor Agonists versus SGLT-2 Inhibitors on ambulatory patient outcomes: A retrospective study
    Kessinger, Haley
    Roberts, Drew
    Knezevich, Emily
    PHARMACOTHERAPY, 2017, 37 (12): : E135 - E135
  • [43] GLP-1 agonists and SGLT-2 inhibitors in adults with sickle cell disease
    Sun, Ryan
    Srivastava, Anand
    Derebail, Vimal K.
    Han, Jin
    Molokie, Robert E.
    Gordeuk, Victor
    Saraf, Santosh L.
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (08) : 1610 - 1612
  • [44] GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection
    Bertoccini, Laura
    Baroni, Marco Giorgio
    DIABETES: FROM RESEARCH TO CLINICAL PRACTICE, VOL 4, 2021, 1307 : 193 - 212
  • [45] SGLT-2 inhibitors and GLP-1 receptor agonists are associated with lower mortality in younger people with type 2 diabetes and a first myocardial infarction between 2016 and 2020
    Londahl, M.
    Puvaneswaralingam, S.
    Uddman, E.
    Filipsson, K.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S132 - S133
  • [46] Socioeconomic dispartities in the use of SGLT-2 inhibitors and GLP-1 receptor antagonists in adults with type 2 diabetes in Germany
    Auzanneau, M.
    Seufert, J.
    Zimny, S.
    Haak, T.
    Zeyfang, A.
    Hugenberg, I.
    Pavel, M.
    Rosenbauer, J.
    Holl, R. W.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S74 - S74
  • [47] Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes - a Danish nationwide observational study
    Falkentoft, Alexander C.
    Andersen, Julie
    Malik, Mariam Elmegaard
    Selmer, Christian
    Gaede, Peter Haulund
    Staehr, Peter Bisgaard
    Hlatky, Mark A.
    Fosbol, Emil
    Kober, Lars
    Torp-Pedersen, Christian
    Gislason, Gunnar H.
    Gerds, Thomas Alexander
    Schou, Morten
    Bruun, Niels E.
    Ruwald, Anne-Christine
    LANCET REGIONAL HEALTH-EUROPE, 2022, 14
  • [48] Lipid Profile Changes Associated with SGLT-2 Inhibitors and GLP-1 Agonists in Diabetes and Metabolic Syndrome
    Premji, Resmi
    Nylen, Eric S.
    Naser, Nejat
    Gandhi, Shruti
    Burman, Kenneth D.
    Sen, Sabyasachi
    METABOLIC SYNDROME AND RELATED DISORDERS, 2022, 20 (06) : 321 - 328
  • [49] Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes
    Lajara, Rosemarie
    POSTGRADUATE MEDICINE, 2019, 131 (08) : 555 - 565
  • [50] Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review
    Gonzalez-Gonzalez, Jose Gerardo
    Diaz Gonzalez-Colmenero, Alejandro
    Millan-Alanis, Juan Manuel
    Lytvyn, Lyubov
    Solis, Ricardo Cesar
    Mustafa, Reem A.
    Palmer, Suetonia C.
    Li, Sheyu
    Hao, Qiukui
    Alvarez-Villalobos, Neri Alejandro
    Vandvik, Per Olav
    Rodriguez-Gutierrez, Rene
    BMJ OPEN, 2021, 11 (07):
12345